Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00421031 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

A Phase 3 study of Vasomotor Symptoms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
540
Enrollment target
20
Study locations

NCT00421031 is a Phase 3 study of Vasomotor Symptoms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 540 participants, above the 132-participant average among 8 other Vasomotor Symptoms trials with a reported enrollment target (309% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00421031, a Phase 3 study of Vasomotor Symptoms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
540 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as its influence on sleep parameters and other health outcomes indicators.

Conditions Studied

Vasomotor Symptoms

Interventions

  • DRUG DVS-233 SR

Study Locations (20)

Florida

  • - Aventura
  • - Fort Myers
  • - Inverness
  • - Miami
  • - New Port Richey
  • - Ocala
  • - Orange City
  • - Pinellas Park
  • - Tampa
  • - West Palm Beach
  • - West Venice

California

  • - San Diego
  • - Stanford

Georgia

  • - Atlanta
  • - Savannah

Alabama

  • - Montgomery

Arizona

  • - Peoria

Colorado

  • - Colorado Springs

Delaware

  • - Newark

Indiana

  • - Newburgh

Trial Details

FieldValue
Enrollment Target 540 participants
Start Date 2003-12
Est. Completion 2004-04
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00421031

The ClinicalTrials.gov registry entry for NCT00421031 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 8 other Vasomotor Symptoms trials with a reported enrollment target (309% higher). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vasomotor Symptoms appearing as the primary indexed condition, and to 1 intervention - of which DVS-233 SR is the first listed.

NCT00421031 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00421031 about?

NCT00421031 is a clinical study titled "Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause". The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as its influence on sleep parameters and other health ou...

What is the current status of trial NCT00421031?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2003-12. Estimated completion is 2004-04.

What conditions does trial NCT00421031 study?

This clinical trial studies the following conditions: Vasomotor Symptoms.

What interventions are being tested in trial NCT00421031?

The interventions under investigation include: DVS-233 SR (DRUG).

Who is sponsoring clinical trial NCT00421031?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00421031 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Vasomotor Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Vasomotor Symptoms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.